ESTRO 2024 - Abstract Book

S2114

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

3. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1397 – 410. 4. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1089 – 103.

5. Kumar V, Misra S, Chaturvedi A. Retroperitoneal Sarcomas- A Challenging Problem. Indian J Surg Oncol. 2012 Sep;3(3):215 – 21.

6. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):852 – 9.

7. Lee JW, Cardona DM, Blazer DG, Kirsch DG. Response to Central Boost Radiation Therapy in an Unresectable Retroperitoneal Sarcoma: A Case Report. Adv Radiat Oncol. 2020 Jun 6;5(6):1375 – 9.

8. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Jan 20;34(3):219 – 26.

9. Soyfer V, Corn BW, Kollender Y, Tempelhoff H, Meller I, Merimsky O. Radiation Therapy for Palliation of Sarcoma Metastases: A Unique and Uniform Hypofractionation Experience. Sarcoma. 2010;2010:927972.

10. Tween H, Peake D, Spooner D, Sherriff J. Radiotherapy for the Palliation of Advanced Sarcomas — The Effectiveness of Radiotherapy in Providing Symptomatic Improvement for Advanced Sarcomas in a Single Centre Cohort. Healthcare. 2019 Oct 18;7(4):120.

11. Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, et al. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol. 2022 Feb 5;7(3):100913.

12. Balagamwala EH, Naik M, Reddy CA, Angelov L, Suh JH, Djemil T, et al. Pain flare after stereotactic radiosurgery for spine metastases. J Radiosurgery SBRT. 2018;5(2):99 – 105.

13. Lindsay AD, Haupt EE, Chan CM, Spiguel AR, Scarborough MT, Zlotecki RA, et al. Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy. Sarcoma. 2018 Apr 1;2018:9132359.

14. Gutkin PM, von Eyben R, Chin A, Donaldson SS, Oh J, Jiang A, et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma. Int J Radiat Oncol. 2022 Nov 15;114(4):771 – 9.

15. Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol Lond Engl. 2019 Jan 29;14:21. 16. Song CW, Terezakis S, Park WY, Paek SH, Kim MS, Cho LC, et al. Preferential Tumor Vascular Damage Is the Common Antitumor Mechanism of High-Dose Hypofractionated Radiation Therapy: SABR, Spatially Fractionated Radiation Therapy, and FLASH Radiation Therapy. Int J Radiat Oncol Biol Phys [Internet]. 2023 [cited 2023 Sep 21]; Available from: http://www.scopus.com/inward/record.url?scp=85161010034&partnerID=8YFLogxK